A single center retrospective study assessing the clinical and laboratory parameters in aged Multiple Sclerosis patients at an Academic MS Center treated with Ocrelizumab
Latest Information Update: 25 Mar 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2021 New trial record
- 27 Feb 2021 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021